MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals

MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec for the treatment of X-linked retinitis...

Related Keywords

London ,City Of ,United Kingdom ,Jason Braco ,Lifesci Communications ,Janssen Pharmaceuticals Inc ,Nasdaq ,Johnson ,Meiragtx Holdings ,Janssen Pharmaceuticals ,Alexandria Forbes ,Quality Control ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,